A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

NCT06827613 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Locally Advanced Non-resectable Breast Cancer
HR+, HER2-, Advanced Breast Cancer

Interventions

DRUG: STAR0602
DRUG: Sacituzumab Govitecan (SG)

Sponsor

Marengo Therapeutics, Inc.